Non-linear association of triglyceride-glucose index with cardiovascular and all-cause mortality in T2DM patients with diabetic kidney disease: NHANES 2001-2018 retrospective cohort study.

Publisher: BioMed Central Country of Publication: England NLM ID: 101147696 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-511X (Electronic) Linking ISSN: 1476511X NLM ISO Abbreviation: Lipids Health Dis Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2002-

Triglycerides*/blood ; Diabetic Nephropathies*/mortality ; Diabetic Nephropathies*/blood ; Cardiovascular Diseases*/mortality ; Cardiovascular Diseases*/blood ; Diabetes Mellitus, Type 2*/mortality ; Diabetes Mellitus, Type 2*/blood ; Diabetes Mellitus, Type 2*/complications ; Blood Glucose*/analysis ; Nutrition Surveys*; Humans ; Male ; Female ; Middle Aged ; Retrospective Studies ; Aged ; Proportional Hazards Models ; Adult ; Risk Factors

Background: The triglyceride glucose (TyG) index is a cutting-edge and highly effective marker of insulin resistance, a crucial factor in the development and exacerbation of diabetic kidney disease (DKD). To date, there has been limited research on how the triglyceride-glucose (TyG) index affects the outlook for patients suffering from DKD.
Methods: In this multicenter retrospective cohort study, the analysis recruited 2,203 DKD patients from the National Health and Nutrition Examination Survey (NHANES) dataset, which covers the US from 2001 to 2018. The research applied a Cox proportional hazards model with multiple variables to investigate the association of the TyG index with mortality outcomes. Restricted cubic splines (RCS) and methods for analyzing threshold effects were employed to identify possible non-linear relationships.
Results: Over nearly 19 years of follow-up, this study captured data on 753 all-cause and 231 cardiovascular disease-specific fatalities. Sophisticated statistical methods, including RCS and smoothing curve adjustments via penalized splines, helped identify distinctive patterns: The baseline TyG index was observed to have a U-shaped pattern related to overall mortality and an L-shape with cardiovascular diseases(CVD) mortality among individuals with DKD. Notably, TyG index below 9.15 for overall mortality and 9.27 for CVD mortality were linked to reduced death rates (HR = 0.65, 95% CI = 0.52-0.82 for all-cause; HR = 0.58, 95% CI = 0.43-0.83 for CVD). On the other hand, TyG index exceeding these benchmarks (greater than 9.15 for all-cause and 9.27 for CVD) correlated with increased all-cause mortality risks (HR = 1.21, 95% CI = 1.02-1.43) and showed a non-significant change in CVD mortality risks (HR = 1.07, 95% CI = 0.83-1.38).
Conclusions: This study emphasizes the non-linear linkage involving the TyG index and death rates due to CVD and other factors in patients with DKD, demonstrating its effectiveness in estimating potential adverse events within this demographic.
(© 2024. The Author(s).)

N Engl J Med. 2011 Mar 03;364(9):829-841. (PMID: 21366474)
Acta Diabetol. 2018 Jun;55(6):603-612. (PMID: 29574497)
Metab Syndr Relat Disord. 2008 Dec;6(4):299-304. (PMID: 19067533)
N Engl J Med. 2015 Oct 29;373(18):1720-32. (PMID: 26510021)
Cardiovasc Diabetol. 2024 Jan 6;23(1):8. (PMID: 38184598)
Prim Care Diabetes. 2020 Apr;14(2):161-167. (PMID: 31466834)
Heart Fail Rev. 2016 Jan;21(1):11-23. (PMID: 26542377)
Diabetes. 2010 Jun;59(6):1487-95. (PMID: 20200314)
Diabetes Res Clin Pract. 2021 Oct;180:109042. (PMID: 34506839)
Ann Intern Med. 2009 May 5;150(9):604-12. (PMID: 19414839)
Nat Rev Mol Cell Biol. 2018 Oct;19(10):654-672. (PMID: 30104701)
Cardiovasc Diabetol. 2022 Aug 23;21(1):161. (PMID: 35999546)
Sci Rep. 2021 Jul 28;11(1):15335. (PMID: 34321520)
Cardiovasc Diabetol. 2021 Feb 11;20(1):43. (PMID: 33573649)
Metabolism. 2011 Dec;60(12):1673-6. (PMID: 21632070)
Am J Physiol Renal Physiol. 2016 Dec 1;311(6):F1087-F1108. (PMID: 27707707)
Diabetol Metab Syndr. 2023 Sep 7;15(1):181. (PMID: 37679825)
J Nephrol. 2022 Jul;35(6):1571-1584. (PMID: 35201595)
Cardiovasc Diabetol. 2023 Sep 4;22(1):239. (PMID: 37667253)
Cardiovasc Diabetol. 2022 Jul 1;21(1):124. (PMID: 35778731)
Clin Exp Hypertens. 2023 Dec 31;45(1):2272581. (PMID: 37902269)
Diabetes. 2006 May;55(5):1456-62. (PMID: 16644705)
Cardiovasc Diabetol. 2023 Jun 13;22(1):138. (PMID: 37312120)
Cardiovasc Diabetol. 2024 Feb 24;23(1):80. (PMID: 38402393)
Case Rep Nephrol Urol. 2014 Jun 28;4(2):137-43. (PMID: 25076962)
BMC Med. 2020 Oct 9;18(1):307. (PMID: 33032595)
Endocr Res. 2023 Oct 2;48(4):94-100. (PMID: 37565769)
Nutr Metab Cardiovasc Dis. 2022 Mar;32(3):596-604. (PMID: 35090800)
Cardiovasc Diabetol. 2022 May 6;21(1):68. (PMID: 35524263)
J Diabetes Investig. 2021 Apr;12(4):557-565. (PMID: 33319507)
BMC Med. 2021 Mar 15;19(1):66. (PMID: 33715620)
Am J Physiol Heart Circ Physiol. 2011 Dec;301(6):H2181-90. (PMID: 21949114)
Diabetes Res Clin Pract. 2022 Jan;183:109119. (PMID: 34879977)
Cardiovasc Diabetol. 2023 Oct 17;22(1):279. (PMID: 37848879)
Neurology. 2019 May 7;92(19):e2286-e2294. (PMID: 30971484)
Kidney Int. 2021 Oct;100(4S):S1-S276. (PMID: 34556256)
Cardiovasc Diabetol. 2023 Nov 22;22(1):320. (PMID: 37993902)
Med Sci Monit. 2023 Jul 08;29:e939482. (PMID: 37421131)
Tex Heart Inst J. 2013;40(5):521-8. (PMID: 24391311)
Cardiovasc Diabetol. 2022 Jun 24;21(1):115. (PMID: 35751060)
Diabetes Care. 2008 Aug;31(8):1550-5. (PMID: 18509205)
Nat Rev Endocrinol. 2014 May;10(5):293-302. (PMID: 24663222)
J Clin Endocrinol Metab. 2010 Jul;95(7):3347-51. (PMID: 20484475)

Keywords: Cardiovascular disease; Diabetic kidney disease; Insulin resistance; Mortality; Triglyceride-glucose index

0 (Triglycerides)
0 (Blood Glucose)

Date Created: 20240817 Date Completed: 20240817 Latest Revision: 20240820

20240820

PMC11330591

10.1186/s12944-024-02249-z

39154178